ArticleRevista da Associacao Medica Brasileira (1992)2026
Serum human epididymis protein 4, endocan, sialyl-Tn, and neopterin in endometrial cancer: a prospective case-control study.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to compare serum levels of endocan, human epididymis protein 4, sialyl-Tn antigen, and neopterin between women with endometrial cancer and asymptomatic healthy controls, and to explore their discriminatory performance in this case-control setting and clinicopathological associations.
methodsProspective case-control study of 133 women with endometrial cancer and 65 healthy controls. Serum biomarkers were measured before treatment by enzyme-linked immunosorbent assays. Discrimination was evaluated using the area under the receiver operating characteristic curve with optimal cut-offs.
resultsEndocan levels were significantly higher in endometrial cancer patients than in controls (p<0.001), with an area under the curve of 0.758. Serum human epididymis protein 4 was also elevated in patients (p<0.001), with an area under the curve of 0.702. Neopterin and sialyl-Tn did not differ significantly between groups. Endocan and human epididymis protein 4 were higher in women with lymphovascular space invasion (both p<0.05); however, these associations did not remain significant after correction for multiple comparisons.
conclusionSerum endocan and human epididymis protein 4 were elevated in endometrial cancer patients compared to asymptomatic healthy controls. Neopterin and sialyl-Tn showed no discriminatory value in this setting. Our findings should be interpreted as exploratory and require validation in clinically relevant cohorts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.